Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.

Get in touch

1800 437 222

Viral hepatitis (A, B & C)

Hepatitis means inflammation of the liver, and it can be caused by a virus or other non-viral causes.  The main difference between the viruses is how they are spread and the effects they have on your health.

Read more...

Prevention

There are safe and effective vaccines that protect you from getting hepatitis A and B.  While there is no vaccine for hep C, by being ‘blood aware’ you can reduce your overall chance of being exposed to the virus.

Read more...

Living with Hepatitis

People with chronic hepatitis can do a number of things to stay healthy including limiting/avoiding alcohol, reducing stress, not smoking, getting regular exercise and eating a healthy diet.

Read more...

Treatment

Effective treatment is available for both chronic hepatitis B and C.  Before you can see a liver specialist to talk about going on treatment, you need to get a referral from your GP first.

Read more...
ContentViewArticle Object
(
    [item:protected] => stdClass Object
        (
            [id] => 296
            [asset_id] => 370
            [title] => New Hep C treatment options - PBAC recommendations announced
            [alias] => new-hep-c-treatment-options-pbac-recommendations-announced
            [title_alias] => 
            [introtext] => Hello,

The recommendations about new hepatitis C treatment options by the Pharmaceutical Benefits Advisory Committee (PBAC), from the March 2015 meeting, have just been published.

We will be translating this new information into practical plain language and circulating it as soon as possible.

Thank you for your continued patience and support in advocating for these new hepatitis C treatment options in Australia.

----------------------
The PBAC recommended the Authority Required listing of ledipasvir/sofosbuvir, and sofosbuvir and daclatasvir for the treatment of chronic Hepatitis C (CHC).

The PBAC reiterated that new treatments for HCV were very effective and listing of these products would offer options for treatment of Genotype 1-6 CHC.

The PBAC considered that it was appropriate for the new all oral treatment to be listed in the General Schedule, rather than Section 100 Highly Specialised Drug Program, to facilitated the longer term objectives for access to treatment, increase treatment rates and better outcomes with a view to treat all patients with CHC over time.

The PBAC did not accept that the treatments are cost-effective at the price proposed by the sponsor.

The PBAC noted that there was a prevalent population of approximately 230,000 patients with CHC in Australia. The estimates of the number of patients treated with the availability of an all oral interferon free treatment, presented by the DUSC, indicated that approximately 62,000 patients could be treated in the next years. Treating this range of patients, the PBAC noted that at the price submitted by the sponsor, the proposed budget impact was exceeding $3 billion over 5 years.

The PBAC advised the Minister:
  • that there is the high clinical need for all oral interferon-free treatments of CHC to be made available on the PBS,
  • that these treatments would be cost-effective at $15,000/QALY range and that there was no basis on which to recommend that any one treatment be more expensive than another,
  • there is a large opportunity cost to health care system. Given this large opportunity cost, the cost of a course of treatment should be set irrespective of the duration, and that other pricing policies be considered,
  • that the current treatment for CHC, such as peginterferon and ribavirin alone and in combination with telaprevir, boceprevir or simeprevir, are no longer cost-effective at the prices currently listed on the PBS.
----------------------
Regards,
Clint Ferndale
CEO


Older news:
[fulltext] => [state] => 1 [mask] => 0 [catid] => 3 [created] => 2015-04-24 07:01:46 [created_by] => 66 [created_by_alias] => [modified] => 2015-04-24 07:09:03 [modified_by] => 66 [checked_out] => 66 [checked_out_time] => 2015-04-24 07:09:03 [publish_up] => 2015-04-24 07:01:46 [publish_down] => 0000-00-00 00:00:00 [images] => [urls] => [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [version] => 2 [parentid] => 0 [ordering] => 116 [metakey] => [metadesc] => [access] => 1 [hits] => 3526 [metadata] => JRegistry Object ( [data:protected] => stdClass Object ( [robots] => [author] => [rights] => [xreference] => ) ) [featured] => 0 [language] => * [xreference] => [category_title] => News & Events [category_alias] => news-a-events [category_access] => 1 [author] => Hepatitis Admin [contactid] => [parent_title] => General [parent_id] => 15 [parent_route] => general [parent_alias] => general [rating] => [rating_count] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [access-view] => 1 ) ) [slug] => 296:new-hep-c-treatment-options-pbac-recommendations-announced [catslug] => 3:news-a-events [parent_slug] => 15:general [readmore_link] => /news-media-a-events/our-news/3-news-a-events/296-new-hep-c-treatment-options-pbac-recommendations-announced [text] => Hello,

The recommendations about new hepatitis C treatment options by the Pharmaceutical Benefits Advisory Committee (PBAC), from the March 2015 meeting, have just been published.

We will be translating this new information into practical plain language and circulating it as soon as possible.

Thank you for your continued patience and support in advocating for these new hepatitis C treatment options in Australia.

----------------------
The PBAC recommended the Authority Required listing of ledipasvir/sofosbuvir, and sofosbuvir and daclatasvir for the treatment of chronic Hepatitis C (CHC).

The PBAC reiterated that new treatments for HCV were very effective and listing of these products would offer options for treatment of Genotype 1-6 CHC.

The PBAC considered that it was appropriate for the new all oral treatment to be listed in the General Schedule, rather than Section 100 Highly Specialised Drug Program, to facilitated the longer term objectives for access to treatment, increase treatment rates and better outcomes with a view to treat all patients with CHC over time.

The PBAC did not accept that the treatments are cost-effective at the price proposed by the sponsor.

The PBAC noted that there was a prevalent population of approximately 230,000 patients with CHC in Australia. The estimates of the number of patients treated with the availability of an all oral interferon free treatment, presented by the DUSC, indicated that approximately 62,000 patients could be treated in the next years. Treating this range of patients, the PBAC noted that at the price submitted by the sponsor, the proposed budget impact was exceeding $3 billion over 5 years.

The PBAC advised the Minister:
  • that there is the high clinical need for all oral interferon-free treatments of CHC to be made available on the PBS,
  • that these treatments would be cost-effective at $15,000/QALY range and that there was no basis on which to recommend that any one treatment be more expensive than another,
  • there is a large opportunity cost to health care system. Given this large opportunity cost, the cost of a course of treatment should be set irrespective of the duration, and that other pricing policies be considered,
  • that the current treatment for CHC, such as peginterferon and ribavirin alone and in combination with telaprevir, boceprevir or simeprevir, are no longer cost-effective at the prices currently listed on the PBS.
----------------------
Regards,
Clint Ferndale
CEO


Older news:
[event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) ) [params:protected] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [print:protected] => [state:protected] => JObject Object ( [_errors:protected] => Array ( ) [task] => [parameters.menu] => JRegistry Object ( [data:protected] => stdClass Object ( [show_title] => [link_titles] => [show_intro] => [show_category] => [link_category] => [show_parent_category] => [link_parent_category] => [show_author] => [link_author] => [show_create_date] => [show_modify_date] => [show_publish_date] => [show_item_navigation] => [show_vote] => [show_icons] => [show_print_icon] => [show_email_icon] => [show_hits] => [show_noauth] => [urls_position] => [menu-anchor_title] => [menu-anchor_css] => [menu_image] => [menu_text] => 1 [page_title] => [show_page_heading] => 0 [page_heading] => [pageclass_sfx] => [menu-meta_description] => [menu-meta_keywords] => [robots] => [secure] => 0 ) ) [article.id] => 296 [list.offset] => 0 [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [filter.published] => 1 [filter.archived] => 2 [filter.language] => ) [user:protected] => JUser Object ( [isRoot:protected] => [id] => 0 [name] => [username] => [email] => [password] => [password_clear] => [usertype] => [block] => [sendEmail] => 0 [registerDate] => [lastvisitDate] => [activation] => [params] => [groups] => Array ( ) [guest] => 1 [lastResetTime] => [resetCount] => [_params:protected] => JRegistry Object ( [data:protected] => stdClass Object ( ) ) [_authGroups:protected] => Array ( [0] => 1 ) [_authLevels:protected] => Array ( [0] => 1 [1] => 1 ) [_authActions:protected] => [_errorMsg:protected] => [_errors:protected] => Array ( ) [aid] => 0 ) [_name:protected] => article [_models:protected] => Array ( [article] => ContentModelArticle Object ( [_context:protected] => com_content.article [_item:protected] => Array ( [296] => stdClass Object ( [id] => 296 [asset_id] => 370 [title] => New Hep C treatment options - PBAC recommendations announced [alias] => new-hep-c-treatment-options-pbac-recommendations-announced [title_alias] => [introtext] => Hello,

The recommendations about new hepatitis C treatment options by the Pharmaceutical Benefits Advisory Committee (PBAC), from the March 2015 meeting, have just been published.

We will be translating this new information into practical plain language and circulating it as soon as possible.

Thank you for your continued patience and support in advocating for these new hepatitis C treatment options in Australia.

----------------------
The PBAC recommended the Authority Required listing of ledipasvir/sofosbuvir, and sofosbuvir and daclatasvir for the treatment of chronic Hepatitis C (CHC).

The PBAC reiterated that new treatments for HCV were very effective and listing of these products would offer options for treatment of Genotype 1-6 CHC.

The PBAC considered that it was appropriate for the new all oral treatment to be listed in the General Schedule, rather than Section 100 Highly Specialised Drug Program, to facilitated the longer term objectives for access to treatment, increase treatment rates and better outcomes with a view to treat all patients with CHC over time.

The PBAC did not accept that the treatments are cost-effective at the price proposed by the sponsor.

The PBAC noted that there was a prevalent population of approximately 230,000 patients with CHC in Australia. The estimates of the number of patients treated with the availability of an all oral interferon free treatment, presented by the DUSC, indicated that approximately 62,000 patients could be treated in the next years. Treating this range of patients, the PBAC noted that at the price submitted by the sponsor, the proposed budget impact was exceeding $3 billion over 5 years.

The PBAC advised the Minister:
  • that there is the high clinical need for all oral interferon-free treatments of CHC to be made available on the PBS,
  • that these treatments would be cost-effective at $15,000/QALY range and that there was no basis on which to recommend that any one treatment be more expensive than another,
  • there is a large opportunity cost to health care system. Given this large opportunity cost, the cost of a course of treatment should be set irrespective of the duration, and that other pricing policies be considered,
  • that the current treatment for CHC, such as peginterferon and ribavirin alone and in combination with telaprevir, boceprevir or simeprevir, are no longer cost-effective at the prices currently listed on the PBS.
----------------------
Regards,
Clint Ferndale
CEO


Older news:
[fulltext] => [state] => 1 [mask] => 0 [catid] => 3 [created] => 2015-04-24 07:01:46 [created_by] => 66 [created_by_alias] => [modified] => 2015-04-24 07:09:03 [modified_by] => 66 [checked_out] => 66 [checked_out_time] => 2015-04-24 07:09:03 [publish_up] => 2015-04-24 07:01:46 [publish_down] => 0000-00-00 00:00:00 [images] => [urls] => [attribs] => {"show_title":"","link_titles":"","show_intro":"","show_category":"","link_category":"","show_parent_category":"","link_parent_category":"","show_author":"","link_author":"","show_create_date":"","show_modify_date":"","show_publish_date":"","show_item_navigation":"","show_icons":"","show_print_icon":"","show_email_icon":"","show_vote":"","show_hits":"","show_noauth":"","urls_position":"","alternative_readmore":"","article_layout":"","show_publishing_options":"","show_article_options":"","show_urls_images_backend":"","show_urls_images_frontend":""} [version] => 2 [parentid] => 0 [ordering] => 116 [metakey] => [metadesc] => [access] => 1 [hits] => 3526 [metadata] => JRegistry Object ( [data:protected] => stdClass Object ( [robots] => [author] => [rights] => [xreference] => ) ) [featured] => 0 [language] => * [xreference] => [category_title] => News & Events [category_alias] => news-a-events [category_access] => 1 [author] => Hepatitis Admin [contactid] => [parent_title] => General [parent_id] => 15 [parent_route] => general [parent_alias] => general [rating] => [rating_count] => [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [access-view] => 1 ) ) [slug] => 296:new-hep-c-treatment-options-pbac-recommendations-announced [catslug] => 3:news-a-events [parent_slug] => 15:general [readmore_link] => /news-media-a-events/our-news/3-news-a-events/296-new-hep-c-treatment-options-pbac-recommendations-announced [text] => Hello,

The recommendations about new hepatitis C treatment options by the Pharmaceutical Benefits Advisory Committee (PBAC), from the March 2015 meeting, have just been published.

We will be translating this new information into practical plain language and circulating it as soon as possible.

Thank you for your continued patience and support in advocating for these new hepatitis C treatment options in Australia.

----------------------
The PBAC recommended the Authority Required listing of ledipasvir/sofosbuvir, and sofosbuvir and daclatasvir for the treatment of chronic Hepatitis C (CHC).

The PBAC reiterated that new treatments for HCV were very effective and listing of these products would offer options for treatment of Genotype 1-6 CHC.

The PBAC considered that it was appropriate for the new all oral treatment to be listed in the General Schedule, rather than Section 100 Highly Specialised Drug Program, to facilitated the longer term objectives for access to treatment, increase treatment rates and better outcomes with a view to treat all patients with CHC over time.

The PBAC did not accept that the treatments are cost-effective at the price proposed by the sponsor.

The PBAC noted that there was a prevalent population of approximately 230,000 patients with CHC in Australia. The estimates of the number of patients treated with the availability of an all oral interferon free treatment, presented by the DUSC, indicated that approximately 62,000 patients could be treated in the next years. Treating this range of patients, the PBAC noted that at the price submitted by the sponsor, the proposed budget impact was exceeding $3 billion over 5 years.

The PBAC advised the Minister:
  • that there is the high clinical need for all oral interferon-free treatments of CHC to be made available on the PBS,
  • that these treatments would be cost-effective at $15,000/QALY range and that there was no basis on which to recommend that any one treatment be more expensive than another,
  • there is a large opportunity cost to health care system. Given this large opportunity cost, the cost of a course of treatment should be set irrespective of the duration, and that other pricing policies be considered,
  • that the current treatment for CHC, such as peginterferon and ribavirin alone and in combination with telaprevir, boceprevir or simeprevir, are no longer cost-effective at the prices currently listed on the PBS.
----------------------
Regards,
Clint Ferndale
CEO


Older news:
[event] => stdClass Object ( [afterDisplayTitle] => [beforeDisplayContent] => [afterDisplayContent] => ) ) ) [__state_set:protected] => 1 [_db:protected] => JDatabaseMySQLi Object ( [name] => mysqli [nameQuote:protected] => ` [nullDate:protected] => 0000-00-00 00:00:00 [dbMinimum:protected] => 5.0.4 [_database:JDatabase:private] => hepqld_joomla [connection:protected] => mysqli Object ( [affected_rows] => 1 [client_info] => mysqlnd 5.0.11-dev - 20120503 - $Id: 76b08b24596e12d4553bd41fc93cccd5bac2fe7a $ [client_version] => 50011 [connect_errno] => 0 [connect_error] => [errno] => 0 [error] => [error_list] => Array ( ) [field_count] => 0 [host_info] => Localhost via UNIX socket [info] => Rows matched: 1 Changed: 1 Warnings: 0 [insert_id] => 0 [server_info] => 5.6.37 [server_version] => 50637 [stat] => Uptime: 2278980 Threads: 1 Questions: 179921224 Slow queries: 56 Opens: 11318166 Flush tables: 1 Open tables: 2000 Queries per second avg: 78.948 [sqlstate] => 00000 [protocol_version] => 10 [thread_id] => 2951971 [warning_count] => 0 ) [count:protected] => 0 [cursor:protected] => 1 [debug:protected] => [limit:protected] => 0 [log:protected] => Array ( ) [offset:protected] => 0 [sql:protected] => UPDATE #__content SET hits = hits + 1 WHERE id = 296 [tablePrefix:protected] => j25_ [utf:protected] => 1 [errorNum:protected] => 0 [errorMsg:protected] => [hasQuoted:protected] => [quoted:protected] => Array ( ) ) [name:protected] => article [option:protected] => com_content [state:protected] => JObject Object ( [_errors:protected] => Array ( ) [task] => [parameters.menu] => JRegistry Object ( [data:protected] => stdClass Object ( [show_title] => [link_titles] => [show_intro] => [show_category] => [link_category] => [show_parent_category] => [link_parent_category] => [show_author] => [link_author] => [show_create_date] => [show_modify_date] => [show_publish_date] => [show_item_navigation] => [show_vote] => [show_icons] => [show_print_icon] => [show_email_icon] => [show_hits] => [show_noauth] => [urls_position] => [menu-anchor_title] => [menu-anchor_css] => [menu_image] => [menu_text] => 1 [page_title] => [show_page_heading] => 0 [page_heading] => [pageclass_sfx] => [menu-meta_description] => [menu-meta_keywords] => [robots] => [secure] => 0 ) ) [article.id] => 296 [list.offset] => 0 [params] => JRegistry Object ( [data:protected] => stdClass Object ( [article_layout] => _:default [show_title] => 1 [link_titles] => 0 [show_intro] => 1 [show_category] => 0 [link_category] => 0 [show_parent_category] => 0 [link_parent_category] => 1 [show_author] => 0 [link_author] => 0 [show_create_date] => 0 [show_modify_date] => 0 [show_publish_date] => 0 [show_item_navigation] => 0 [show_vote] => 0 [show_readmore] => 1 [show_readmore_title] => 1 [readmore_limit] => 100 [show_icons] => 0 [show_print_icon] => 0 [show_email_icon] => 0 [show_hits] => 0 [show_noauth] => 0 [urls_position] => 0 [show_publishing_options] => 1 [show_article_options] => 1 [show_urls_images_frontend] => 0 [show_urls_images_backend] => 0 [targeta] => 0 [targetb] => 0 [targetc] => 0 [float_intro] => right [float_fulltext] => right [category_layout] => _:blog [show_category_heading_title_text] => 0 [show_category_title] => 0 [show_description] => 0 [show_description_image] => 0 [maxLevel] => -1 [show_empty_categories] => 0 [show_no_articles] => 1 [show_subcat_desc] => 1 [show_cat_num_articles] => 1 [show_base_description] => 0 [maxLevelcat] => -1 [show_empty_categories_cat] => 0 [show_subcat_desc_cat] => 1 [show_cat_num_articles_cat] => 1 [num_leading_articles] => 1 [num_intro_articles] => 4 [num_columns] => 2 [num_links] => 4 [multi_column_order] => 0 [show_subcategory_content] => 0 [show_pagination_limit] => 1 [filter_field] => hide [show_headings] => 1 [list_show_date] => 0 [date_format] => [list_show_hits] => 1 [list_show_author] => 1 [orderby_pri] => none [orderby_sec] => rdate [order_date] => published [show_pagination] => 2 [show_pagination_results] => 1 [show_feed_link] => 1 [feed_summary] => 0 [feed_show_readmore] => 0 [menu_text] => 1 [show_page_heading] => 0 [secure] => 0 [page_title] => Latest News [page_description] => Hepatitis Queensland [page_rights] => [robots] => [page_heading] => Latest News ) ) [filter.published] => 1 [filter.archived] => 2 [filter.language] => ) [event_clean_cache:protected] => onContentCleanCache [_errors:protected] => Array ( ) ) ) [_basePath:protected] => /home/hepqld/public_html/components/com_content [_defaultModel:protected] => article [_layout:protected] => default [_layoutExt:protected] => php [_layoutTemplate:protected] => _ [_path:protected] => Array ( [template] => Array ( [0] => /home/hepqld/public_html/templates/if_960_j25/html/com_content/article/ [1] => /home/hepqld/public_html/components/com_content/views/article/tmpl/ ) [helper] => Array ( [0] => /home/hepqld/public_html/components/com_content/helpers/ ) ) [_template:protected] => /home/hepqld/public_html/templates/if_960_j25/html/com_content/article/default.php [_output:protected] => [_escape:protected] => htmlspecialchars [_charset:protected] => UTF-8 [_errors:protected] => Array ( ) [baseurl] => [document] => JDocumentHTML Object ( [_links] => Array ( ) [_custom] => Array ( ) [template] => [baseurl] => [params] => [_file] => [_template:protected] => [_template_tags:protected] => Array ( ) [_caching:protected] => [title] => New Hep C treatment options - PBAC recommendations announced [description] => Hepatitis Queensland [link] => [base] => http://www.hepqld.asn.au/news-media-a-events/our-news/3-news-a-events/296-new-hep-c-treatment-options-pbac-recommendations-announced [language] => en-gb [direction] => ltr [_generator] => Joomla! - Open Source Content Management [_mdate] => [_tab] => [_lineEnd] => [_charset] => utf-8 [_mime] => text/html [_namespace] => [_profile] => [_scripts] => Array ( [/media/system/js/mootools-core.js] => Array ( [mime] => text/javascript [defer] => [async] => ) [/media/system/js/core.js] => Array ( [mime] => text/javascript [defer] => [async] => ) [/media/system/js/caption.js] => Array ( [mime] => text/javascript [defer] => [async] => ) ) [_script] => Array ( [text/javascript] => window.addEvent('load', function() { new JCaption('img.caption'); }); ) [_styleSheets] => Array ( ) [_style] => Array ( ) [_metaTags] => Array ( [http-equiv] => Array ( [content-type] => text/html ) [standard] => Array ( [keywords] => Hepatitis Queensland [rights] => [author] => Hepatitis Admin ) ) [_engine] => [_type] => html [_errors:protected] => Array ( ) ) [pageclass_sfx] => )

New Hep C treatment options - PBAC recommendations announced

Hello,

The recommendations about new hepatitis C treatment options by the Pharmaceutical Benefits Advisory Committee (PBAC), from the March 2015 meeting, have just been published.

We will be translating this new information into practical plain language and circulating it as soon as possible.

Thank you for your continued patience and support in advocating for these new hepatitis C treatment options in Australia.

----------------------
The PBAC recommended the Authority Required listing of ledipasvir/sofosbuvir, and sofosbuvir and daclatasvir for the treatment of chronic Hepatitis C (CHC).

The PBAC reiterated that new treatments for HCV were very effective and listing of these products would offer options for treatment of Genotype 1-6 CHC.

The PBAC considered that it was appropriate for the new all oral treatment to be listed in the General Schedule, rather than Section 100 Highly Specialised Drug Program, to facilitated the longer term objectives for access to treatment, increase treatment rates and better outcomes with a view to treat all patients with CHC over time.

The PBAC did not accept that the treatments are cost-effective at the price proposed by the sponsor.

The PBAC noted that there was a prevalent population of approximately 230,000 patients with CHC in Australia. The estimates of the number of patients treated with the availability of an all oral interferon free treatment, presented by the DUSC, indicated that approximately 62,000 patients could be treated in the next years. Treating this range of patients, the PBAC noted that at the price submitted by the sponsor, the proposed budget impact was exceeding $3 billion over 5 years.

The PBAC advised the Minister:
  • that there is the high clinical need for all oral interferon-free treatments of CHC to be made available on the PBS,
  • that these treatments would be cost-effective at $15,000/QALY range and that there was no basis on which to recommend that any one treatment be more expensive than another,
  • there is a large opportunity cost to health care system. Given this large opportunity cost, the cost of a course of treatment should be set irrespective of the duration, and that other pricing policies be considered,
  • that the current treatment for CHC, such as peginterferon and ribavirin alone and in combination with telaprevir, boceprevir or simeprevir, are no longer cost-effective at the prices currently listed on the PBS.
----------------------
Regards,
Clint Ferndale
CEO


Older news:
© copyright 2013 | All Rights Reserved | Website design Brisbane by iFactory